Cargando…

A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis

BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that infla...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Hiroshi, Takasaki, Akihisa, Nakamura, Yasuhiko, Numa, Fumitaka, Sugino, Norihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207622/
https://www.ncbi.nlm.nih.gov/pubmed/25331066
http://dx.doi.org/10.1186/s13048-014-0100-8
_version_ 1782341004436701184
author Tamura, Hiroshi
Takasaki, Akihisa
Nakamura, Yasuhiko
Numa, Fumitaka
Sugino, Norihiro
author_facet Tamura, Hiroshi
Takasaki, Akihisa
Nakamura, Yasuhiko
Numa, Fumitaka
Sugino, Norihiro
author_sort Tamura, Hiroshi
collection PubMed
description BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. METHODS: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2’-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups. RESULTS: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%, respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml). Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml). CONCLUSIONS: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the ovary in patients with endometriosis.
format Online
Article
Text
id pubmed-4207622
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42076222014-10-28 A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis Tamura, Hiroshi Takasaki, Akihisa Nakamura, Yasuhiko Numa, Fumitaka Sugino, Norihiro J Ovarian Res Research BACKGROUND: Additional treatment with a gonadotropin-releasing hormone (GnRH) agonist (GnRHa) before IVF-ET (ultralong GnRHa therapy) has been reported to improve the outcome of IVF-ET in endometriosis patients. However, the mechanism of ultralong GnRHa therapy is unclear. It is suggested that inflammatory cytokines and oxidative stress contribute to infertility in endometriosis patients. Therefore, in order to search a possible mechanism of ultralong GnRHa therapy, we investigated the effect of ultralong GnRHa therapy on intrafollicular concentrations of tumor necrosis factor alpha (TNFα), oxidative stress markers, and antioxidants in patients with endometriosis. METHODS: Twenty-three infertile women with Stage III or IV endometriosis were recruited for this study. Eleven patients received three courses of GnRHa (1.8 mg s.c. every 28 days), followed by a standard controlled ovarian hyperstimulation (COH) for IVF-ET (ultralong group). The other 12 patients received a standard COH with mid-luteal phase GnRHa down-regulation (control group). The numbers of matured follicles and retrieved oocytes, fertilization rates, implantation rates, clinical pregnancy rate, and intrafollicular concentrations of TNFα, 8-hydroxy-2’-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL) as oxidative stress markers, and melatonin and Cu,Zu-superoxide dismutase (Cu,Zn-SOD) as antioxidants were compared between the two groups. RESULTS: The numbers of mature follicles and retrieved oocytes, and fertilization rates did not differ between the two groups. Implantation rates and pregnancy rates tended to be higher in the ultralong group (21.4% and 27.3%, respectively) compared with the control group (8.3% and 8.3%, respectively). TNFα concentrations in the follicular fluid were significantly lower in the ultralong group (5.8 ± 3.2 pg/ml) than those in the control group (10.6 ± 3.2 pg/ml). Follicular concentrations of 8-OHdG concentrations were significantly lower in the ultralong group (5.7 ± 1.6 ng/ml) than those in the control group (6.6 ± 1.5 ng/ml), while melatonin concentrations were significantly higher in the ultralong group (139 ± 46 pg/ml) compared with the control group (86 ± 27 pg/ml). CONCLUSIONS: Ultralong GnRHa therapy reduces the detrimental effects of cytotoxic cytokines and oxidative stress in the ovary in patients with endometriosis. BioMed Central 2014-10-21 /pmc/articles/PMC4207622/ /pubmed/25331066 http://dx.doi.org/10.1186/s13048-014-0100-8 Text en © Tamura et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Tamura, Hiroshi
Takasaki, Akihisa
Nakamura, Yasuhiko
Numa, Fumitaka
Sugino, Norihiro
A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title_full A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title_fullStr A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title_full_unstemmed A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title_short A pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in IVF-ET patients with endometriosis
title_sort pilot study to search possible mechanisms of ultralong gonadotropin-releasing hormone agonist therapy in ivf-et patients with endometriosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207622/
https://www.ncbi.nlm.nih.gov/pubmed/25331066
http://dx.doi.org/10.1186/s13048-014-0100-8
work_keys_str_mv AT tamurahiroshi apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT takasakiakihisa apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT nakamurayasuhiko apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT numafumitaka apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT suginonorihiro apilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT tamurahiroshi pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT takasakiakihisa pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT nakamurayasuhiko pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT numafumitaka pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis
AT suginonorihiro pilotstudytosearchpossiblemechanismsofultralonggonadotropinreleasinghormoneagonisttherapyinivfetpatientswithendometriosis